CCR2 INHIBITOR CCX140 EFFECTIVE IN PHASE 2 CLINICAL TRIAL IN DIABETIC NEPHROPATHY

被引：0
|
作者：
de Zeeuw, Dick [1 ]
Henkel, Elena [2 ]
Psottova, Jana [3 ]
Paragh, Gyorgy [4 ]
Mehling, Heidrun [5 ]
Hasslacher, Christopher [6 ]
Potarca, Antonia [7 ]
Bekker, Pirow [8 ]
Schall, Thomas J. [9 ]
机构：
[1] Univ Med Ctr Groningen, Clin Pharm & Pharmacol, NL-9713 AV Groningen, Netherlands
[2] Tech Univ Dresden, Diabet, D-01062 Dresden, Germany
[3] Diainmed, Diabet, Prague, Czech Republic
[4] Univ Debrecen, Diabet, Debrecen, Hungary
[5] Free Univ Berlin, Diabet, Berlin, Germany
[6] Heidelberg Univ, Diabet, Heidelberg, Germany
[7] ChemoCentryx, Clin Operat, Mountain View, CA USA
[8] ChemoCentryx, Med & Clin Affairs, Mountain View, CA USA
[9] ChemoCentryx, R&D, Mountain View, CA USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2015年 / 30卷
关键词：
D O I：
10.1093/ndt/gfv195.1
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
SP457
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The CCR2 Antagonist CCX140 Improves Renal Function and Hyperglycemia in Diabetic Mice Expressing Human CCR2
    Powers, Jay P.
    Sullivan, Timothy J.
    Miao, Zhenhua
    Zhao, Niky
    Berahovich, Robert D.
    Ertl, Linda
    Walters, Matthew J.
    Dang, Ton
    Miao, Shichang
    Jaen, Juan C.
    Schall, Thomas J.
    DIABETES, 2013, 62 : A27 - A27
  • [2] THE CCR2 ANTAGONIST CCX140 IMPROVES RENAL FUNCTION IN TWO TYPES OF DIABETIC MICE EXPRESSING HUMAN CCR2
    Powers, Jay
    Sullivan, Timothy
    Miao, Zhenhua
    Berahovich, Rob
    Ertl, Linda
    Walters, Matthew
    Miao, Shichang
    Jaen, Juan
    Schall, Thomas
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 51 - 51
  • [3] The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
    de Zeeuw, Dick
    Bekker, Pirow
    Henkel, Elena
    Hasslacher, Christopher
    Gouni-Berthold, Ioanna
    Mehling, Heidrun
    Potarca, Antonia
    Tesar, Vladimir
    Heerspink, Hiddo J. Lambers
    Schall, Thomas J.
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (09): : 687 - 696
  • [4] CLINICAL DEVELOPMENT OF CCR2 ANTAGONISTS CCX140-B AND CCX872-B
    Bekker, Pirow
    Charvat, Trevor
    Miao, Shichang
    Dairaghi, Dan
    Lohr, Lisa
    Sullivan, Timothy
    Seitz, Lisa
    Miao, Zhenhua
    Powers, Jay
    Jaen, Juan
    Schall, Thomas
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 17 - 17
  • [5] CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice
    Sullivan, Timothy
    Miao, Zhenhua
    Dairaghi, Daniel J.
    Krasinski, Antoni
    Wang, Yu
    Zhao, Bin N.
    Baumgart, Trageen
    Ertl, Linda S.
    Pennell, Andrew
    Seitz, Lisa
    Powers, Jay
    Zhao, Ruiping
    Ungashe, Solomon
    Wei, Zheng
    Boring, Landin
    Tsou, Chia-Lin
    Charo, Israel
    Berahovich, Robert D.
    Schall, Thomas J.
    Jaen, Juan C.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2013, 305 (09) : F1288 - F1297
  • [6] Phase 1 Clinical Evaluation of the CCR2 Antagonist CCX872-B
    Bekker, Pirow
    Charvat, Trevor
    Miao, Shichang
    Lohr, Lisa
    Sullivan, Timothy
    Miao, Zhenhua
    Powers, Jay
    Jaen, Juan
    Schall, Thomas J.
    DIABETES, 2013, 62 : A292 - A293
  • [7] Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer.
    Noel, Marcus Smith
    Hezel, Aram F.
    Linehan, David
    Wang-Gillam, Andrea
    Eskens, Ferry
    Sleijfer, Stefan
    Desar, Ingrid
    Erdkamp, Frans
    Wilmink, Johanna
    Diehl, Janet
    Potarca, Antonia
    Zhao, Niky
    Deng, Jun
    Lohr, Lisa
    Miao, Shichang
    Charo, Israel
    Singh, Rajinder
    Schall, Thomas J.
    Bekker, Pirow
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [8] Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis
    Parker, Richard
    Walters, Matthew
    Ertl, Linda
    Ebsworth, Karen
    Tan, Joanne
    McMahon, Jeff
    Powers, Jay
    Adams, David
    Jaen, Juan
    Schall, Tom
    LANCET, 2014, 383 : 78 - 78
  • [9] THERAPEUTIC USE OF A CLINICAL STAGE CCR2 INHIBITOR, CCX872, IMPROVES OBESITY ASSOCIATED STEATOHEPATITIS IN MICE
    Parker, R.
    Walters, M. J.
    Ertle, L.
    Ebsworth, K.
    Tan, J.
    Sietz, L.
    McMahon, J.
    Dairaghi, D.
    Powers, J.
    Adams, D.
    Jaen, J.
    Schall, T.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S149 - S149
  • [10] The inhibition of CCR2 to modify the microenvironment in pancreatic cancer mouse model and to support the profiling of the CCR2 inhibitor CCX872-B in patients.
    Wang-Gillam, Andrea
    Noel, Marcus Smith
    Sleijfer, Stefan
    Jung, Heiyoun
    Lohr, Lisa
    Zhao, Niky
    Miao, Shichang
    Potarca, Antonia
    Charo, Israel
    Bekker, Petrus
    Schall, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345